Results 91 to 100 of about 11,328,563 (174)

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials

Medical Sciences
Background: Anti-amyloid monoclonal antibodies represent the first disease-modifying therapeutic strategy targeting amyloid-β pathology in early Alzheimer’s disease (AD).
Albert Vamanu, Alexandra Mastaleru, Thomas Gabriel Schreiner, Gabriela Popescu, Adina Maria Roceanu, Andrei Ionut Cucu, Alexandru Patrascu, Georgiana-Anca Vulpoi, Robert-Valentin Bilcu, Romica Sebastian Cozma, Raluca Olariu, Cătălina Elena Bistriceanu, Roxana Covali, Dan Iulian Cuciureanu, Alin Ciubotaru   +14 more
doaj   +1 more source

Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer’s disease [PDF]

Alzheimer’s disease is the most prevalent form of dementia in the elderly, which is clinically characterized by a gradual and progressive deterioration of cognitive functions.
Edison, Paul, Aljuhani, Manal, Ashraf, Azhaar   +2 more
core   +1 more source

Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab

Alzheimer’s Research & Therapy
Objective Report a case of an apolipoprotein E (APOE)ε2 carrier receiving lecanemab who developed late onset intracerebral hemorrhage (ICH) following amyloid-related imaging abnormalities-hemorrhage (ARIA-H). Method We detail the history and neuroimaging
Sung Ji, Michael Rosenbloom
doaj   +1 more source

Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System

Summary Background The benefits of amyloid-β monoclonal antibodies for Alzheimer’s disease are tempered by the risk of amyloid-related imaging abnormalities (ARIA). Detailed real-world characterization of ARIA, including incidence, timing, radiologic severity and localization, natural history, and ...
Neguine Rezaii, John R Dickson, Jeremy N Ford, Yingnan He, Yuta Katsumi, Liliana Ramirez-Gomez, Alice Lam, Hina Shah, Steven Arnold, Marina Avetisyan, Sheena R Baratono, Alaina Bennett, Paul M. Butler, Diane Chan, Matthew DeSalvo, Mark Eldaief, Rose Gallagher, Stephen Gomperts, Anna Goodheart, Mark Albers, Raymond Y Huang, Isaiah Kletenik, Sophal Lam, Michael McCormick, Samantha Milano, Nathan Praschan, Saurabh Rohatgi, Elmira Hasanzadeh, Javier Romero, Alberto Serrano Pozo, Abigail Shaughnessey, Andrew Stern, Jason You, Geoffrey Young, Jasmeer Chhatwal, Kirk R Daffner, Michael G Erkkinen, Seth Gale, Teresa Gomez-Isla, Gad A Marshall, Scott M McGinnis, Dennis Selkoe, Hyun-Sik Yang, Wai-Ying Wendy Yau, Sudeshna Das, Bradford C Dickerson   +45 more
openaire   +1 more source

Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience

Alzheimer’s Research & Therapy
Background Anti-amyloid monoclonal antibodies are entering clinical practice for early symptomatic Alzheimer’s disease (AD), but European real-world data on feasibility, safety, and biomarker monitoring remain limited.
Federica Agosta, Giordano Cecchetti, Edoardo G. Spinelli, Alma Ghirelli, Giulia Rugarli, Stefano Pisano, Federico Coraglia, Elisa Canu, Veronica Castelnovo, Elisa Sibilla, Anna Gilioli, Chiara Tripodi, Fabiola Freri, Alessandra Bianchi, Paolo Vezzulli, Sonia Calloni, Andrea Falini, Ana Maria Samanes Gajate, Andrea Panzacchi, Gino Pepe, Camilla Ferri, Arturo Chiti, Massimo Filippi   +22 more
doaj   +1 more source

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients [PDF]

, 2017
BACKGROUND: Amyloid-related imaging abnormalities (ARIA) consist of ARIA-E (with effusion or edema) and ARIA-H (hemosiderin deposits [HDs]). OBJECTIVES: To address accurate ascertainment of ARIA identification, a final magnetic resonance imaging (MRI)
Bogert, J, Ketter, N, Brashear, HR, Gass, A, Arrighi, HM, Barkhof, F, Miaux, Y, Purcell, DD, Di, J   +8 more
core   +1 more source

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer’s disease patients [PDF]

BACKGROUND: Amyloid-related imaging abnormalities (ARIA) are a common and potentially dangerous side effect in anti-amyloid therapies, creating a need for tools to assess ARIA risk.
Hok-A-Hin, YS, Bejanin, A, Vermunt, L, Vijverberg, EGB, Oosthoek, M, Zsadanyi, SE, Barkhof, F, Blujdea, ER, Visser, A, Schut, MC, Alcolea, D, del Campo, M, Teunissen, CE, Avilés, MP, van der Flier, WM, Veld, SGJGI   +15 more
core   +1 more source

Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease

INNOVATIONS in Pharmacy
The Food and Drug Administration granted traditional approval of lecanemab for the treatment of Alzheimer’s disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets
Connie Yoon, Corey Groff, Olivia Criss
doaj   +1 more source

Utility of APOE testing for reducing ARIA under probabilistic stopping rates to treat with anti-amyloid therapy for ε4-homozygote patients: A simulation study

JAR Life
Background: APOE ε4/ε4 genotype increases the risk of Amyloid-Related Imaging Abnormalities (ARIA) from anti-amyloid antibody treatment (AAT). While guidelines recommend testing, its practical utility depends on the resulting probability (p) that ...
Kenichiro Sato, Yoshiki Niimi, Masanori Kurihara, Ryoko Ihara, Atsushi Iwata, Takeshi Iwatsubo   +5 more
doaj   +1 more source

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities ...
Alexander Wallace, Oliver Zhou, Minh‐Nguyet Hoang, Gabriella Porter, Claudia Padilla, Cindy Marshall   +5 more
doaj   +1 more source